Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$21.32 USD

21.32
1,145,075

-0.18 (-0.84%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $21.33 +0.01 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for NTLA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Intellia Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 912 1,193 749 597 280
Receivables 36 4 2 2 5
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 50 20 19 17 5
Total Current Assets 998 1,217 769 617 289
Net Property & Equipment 33 28 21 16 18
Investments & Advances 112 102 395 0 5
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 43 41 30 5 3
Total Assets 1,301 1,520 1,294 676 334
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 7 5 10 10 4
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 67 61 43 26 13
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 22 44 64 23 13
Total Current Liabilities 115 127 126 64 36
Mortgages 0 0 0 0 0
Deferred Taxes/Income 39 20 63 51 16
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 24 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 251 285 254 149 64
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,711 2,420 1,746 962 570
Retained Earnings -1,658 -1,177 -703 -435 -301
Other Equity -2 -7 -3 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,050 1,236 1,040 527 270
Total Liabilities & Shareholder's Equity 1,301 1,520 1,294 676 334
Total Common Equity 1,050 1,236 1,040 527 270
Shares Outstanding 89.50 78.60 73.40 59.00 48.80
Book Value Per Share 11.73 15.72 14.17 8.93 5.53

Fiscal Year End for Intellia Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 912 855 908 934
Receivables NA 36 6 5 5
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 50 32 26 25
Total Current Assets NA 998 893 940 964
Net Property & Equipment NA 33 34 33 32
Investments & Advances NA 112 155 186 253
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 43 42 41 41
Total Assets NA 1,301 1,243 1,323 1,418
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 7 4 12 7
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 67 58 50 45
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 22 13 22 35
Total Current Liabilities NA 115 92 100 103
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 39 13 13 14
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 251 206 218 227
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,711 2,567 2,513 2,474
Retained Earnings NA -1,658 -1,526 -1,404 -1,280
Other Equity NA -2 -4 -4 -3
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 1,050 1,037 1,105 1,191
Total Liabilities & Shareholder's Equity NA 1,301 1,243 1,323 1,418
Total Common Equity 0 1,050 1,037 1,105 1,191
Shares Outstanding 96.10 89.50 88.40 88.40 88.10
Book Value Per Share 0.00 11.73 11.74 12.50 13.52